• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cerus Corporation

Cerus posts Street-beating Q2 results

August 4, 2017 By Sarah Faulkner

Cerus Corp.

Shares in Cerus (NSDQ:CERS) fell today despite the company beating expectations on Wall Street with its second quarter results. The Concord, Calif.-based company posted a net loss of -$17.1, or -16¢ per share, on sales of $9.5 million for the 3 months ended June 30, for bottom-line growth of 6% on sales growth of 3% compared […]

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Cerus Corporation

Cerus inks $40m loan deal with Oxford Finance

August 2, 2017 By Sarah Faulkner

Cerus Corp.

Cerus (NSDQ:CERS) said today that it inked a $40 million amended growth capital credit facility with Oxford Finance. Concord, Calif.-based Cerus received a $30 million loan when it closed the deal, according to the company, and can draw another $10 million contingent upon a specified sales milestone. “Oxford continues to be an invaluable partner. Their appreciation […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Wall Street Beat Tagged With: Cerus Corporation

Cerus lowers Intercept sales guidance after Fresenius Kabi supply snafu

May 23, 2017 By Sarah Faulkner

Cerus Corp.

Cerus (NSDQ:CERS) said today that it expects a U.S. supply shortage of Fresenius Kabi’s (NYSE:FMS) platelet additive solution will impact blood centers that use PAS to produce Intercept platelets. The pending shortage is due to “an unanticipated delay” in FDA approval of a plastic component used to manufacture the PAS container. The original component was discontinued […]

Filed Under: Drug-Device Combinations, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Cerus Corporation, Fresenius

First patient transfused with Intercept red blood cells in Phase III trial

May 15, 2017 By Sarah Faulkner

Cerus Corp.

Cerus (NSDQ:CERS) said today that the 1st patient was transfused in Puerto Rico in a clinical trial comparing red blood cells processed with its Intercept blood system to conventional red blood cells. Concord, Calif.-based Cerus is developing the Intercept blood system, a pathogen reduction device designed to inactivate a broad range of viruses, bacteria, parasites […]

Filed Under: Clinical Trials, Featured, Wall Street Beat Tagged With: Cerus Corporation

Cerus lands $47m for Intercept red blood cell system

May 10, 2017 By Sarah Faulkner

Cerus Corp.

Cerus (NSDQ:CERS) said today that it exercised $46.6 million in additional options from its contract with the Biomedical Advanced Research & Development Authority, a part of the U.S. Dept. of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. Concord, Calif.-based Cerus is developing the Intercept blood system, a pathogen reduction device designed […]

Filed Under: Clinical Trials, Featured, Funding Roundup, Wall Street Beat Tagged With: Cerus Corporation

Cerus shares fall after Q1 miss

May 4, 2017 By Sarah Faulkner

Cerus Corp.

Shares in Cerus Corp. (NSDQ:CERS) fell -18% today after the company missed expectations on Wall Street with its 1st quarter results. The Concord, Calif.-based company posted a net loss of -$18.7 million, or -18¢ per share, on sales of $7 million for the 3 months ended March 31, for bottom-line loss of -10.7% on sales growth of […]

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Cerus Corporation

Cerus raises funds for phase III trial of Intercept red blood cell system

December 19, 2016 By Sarah Faulkner

Cerus Corp.

Cerus Corporation (NSDQ:CERS) said today that it exercised $10.8 million in additional options from its contract with the Biomedical Advanced Research & Development Authority, a part of the U.S. Dept. of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. The funds will go towards in vitro pathogen inactivation and red blood cell […]

Filed Under: Clinical Trials, Featured, Funding Roundup, Regulatory/Compliance, Wall Street Beat Tagged With: Cerus Corporation

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS